Clínica Gastrobese
Passo Fundo, Rio Grande do Sul, 99010112, Brazil
NCT Number: NCT00951093
The hypothesis of this study was that gastric bypass (GBP) ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Passo Fundo, Rio Grande do Sul, 99010112, Brazil
The investigators studied the impact of this surgical procedure on GERD in patients with morbid obesity.
Esophageal syndromes were evaluated according to the Montreal Consensus, where troublesome symptoms were defined as score ≥ 2 on a validated questionnaire of symptoms for Portuguese language along with esophageal syndromes with injury assessed through upper endoscopy.
Esophageal acid exposure was determined through 24h pH monitoring. Increased acid exposure was characterized when total esophageal pH < 4 for at least 4% of the total monitoring time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Prevalence of typical reflux syndrome according to the Montreal Consensus. This Consensus institutes that GERD can be outlined when troublesome symptoms and/or complications induced by reflux of the gastric content back to the esophagus are present.
In order to assess such troublesome symptoms a validated questionnaire translated into Portuguese language was used.
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Syndromes with esophageal injury were represented exclusively by the presence of reflux esophagitis
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Prevalence of GERD in patients characterized according to troublesome symptomatic syndromes assessed through a validated questionnaire based on the Montreal Consensus.
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Esophageal acid exposure was measured through 24h pH monitoring. During the entire period, esophageal pH was measured and recorded as the percent of time pH was below 4.
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Esophageal acid exposure was measured through 24h pH monitoring. Esophageal pH was measured and recorded as the percent of time pH was below 4 while participant in upright position
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Esophageal acid exposure was measured through 24h pH monitoring. Esophageal pH was measured and recorded as the percent of time pH was below 4 while participant in supine position
Time frame: Before GBP, 6 months after GBP and 39 months after GBP
Increased Acid Exposure occurs when esophageal pH is <4 for a period longer than 4% of the total test time on a 24h pH monitoring.
Clinica Gastrobese
Other
The Impact of Gastric Bypass on Gastroesophageal Reflux Disease in Patients With Morbid Obesity: a Prospective Study Based on Montreal Consensus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03692455
Body Weight, Deglutition Disorders
Passo Fundo, Rio Grande do Sul, Brazil
View Trial DetailsNCT07560787
Body Weight, Deglutition Disorders
Van, Turkey (Türkiye)
View Trial DetailsNCT05405816
Body Weight, Deglutition Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05107219
Barrett Esophagus, Deglutition Disorders
Scottsdale, Arizona, United States
View Trial Details